Biocon FY26 results: ₹16,927 cr revenue, 10% dividend

Board meeting: FY26 results, dividend, and BBL integration plan

Biocon Ltd. said its board met on May 7, 2026, and approved the audited standalone and consolidated financial results for the year ended March 31, 2026. Alongside the results, the board recommended a final dividend and cleared a set of corporate actions linked to the full integration of Biocon Biologics Limited (BBL). The company positioned the integration as a step toward running a unified global biopharmaceutical business under the listed parent. The same board outcome also included governance items such as auditor changes, board appointments, and a new employee incentive plan. The announcements were made through exchange filings, with the source cited as BSE.

FY26 financial snapshot: revenue and profit figures disclosed

In the compilation of disclosures provided, Biocon’s consolidated revenue for FY2026 was stated as ₹16,927.0 crore (₹1,69,270 million). Another excerpt in the same material mentioned consolidated FY26 revenue of ₹15,261.7 crore (₹1,52,617 million) as a comparison point for the prior year, and also referenced consolidated total income of ₹17,269.5 crore (₹1,72,695 million) versus ₹16,469.9 crore (₹1,64,699 million) in the previous year. For profit, one section stated consolidated net profit of ₹1,429.4 crore (₹14,294 million) for FY2026. Another section cited consolidated net profit of ₹368.8 crore (₹3,688 million) for the year. Separately, the standalone numbers included revenue of ₹2,346.4 crore (₹23,464 million) and net profit of ₹37.2 crore (₹372 million).

Final dividend: 10% (₹0.50 per share) and key dates

The board recommended a final dividend of 10%, translating to ₹0.50 per equity share with a face value of ₹5. The dividend is subject to shareholder approval at Biocon’s upcoming Annual General Meeting. The company fixed July 3, 2026 as the record date for determining shareholder eligibility. The AGM is scheduled for August 6, 2026 (the 48th AGM). The payout is scheduled on or before August 31, 2026, subject to approval.

BBL stake purchase: moving toward 100% ownership

A central board decision was to acquire the remaining equity stake in Biocon Biologics Limited held by minority shareholders, with the stated objective of making BBL a wholly owned subsidiary. The material described the transaction as an acquisition of approximately 2% of BBL equity through a special share issuance arrangement. One excerpt quantified the consideration as up to ₹330.73 crore via a preferential issue. Another excerpt described a share swap structure through which Biocon would issue up to 87,92,317 equity shares to acquire remaining BBL shares from employees and other shareholders. The preferential issue was stated at an issue price of ₹376.16 per share. The stated rationale was to simplify BBL’s reporting and governance structure, and to streamline consolidation under the parent.

Integration timeline and approvals to watch

The provided material said the completion of the remaining BBL acquisition is targeted for June 30, 2026. It also noted that delays in securing approvals could affect the integration timeline. The acquisition and share issuance are described as being subject to shareholder and regulatory approvals. In earlier board actions cited in the same compilation, Biocon had granted in-principle approval for acquiring the remaining ~2% of BBL from employee shareholders and others, with consideration discharged through a preferential allotment of Biocon shares. The board meeting that referenced the in-principle approval was stated to have commenced at 4:45 PM and concluded at 6:45 PM.

Auditors and governance: Batliboi appointment and board changes

Biocon recommended appointing S. R. Batliboi & Associates LLP as statutory auditors for a five-year term, starting from the conclusion of the 48th AGM, succeeding B S R & Co. LLP. The company also announced several board appointments recommended to be effective August 1, 2026. The names listed as Independent Directors were Rajiv Malik, Daniel Bradbury, Peter Baron Piot, Arun Suresh Chandavarkar, and Nivruti Rai. The board also recommended Thomas Jason Roberts as a Non-Executive Non-Independent Director. Separately, the company designated Dr. Anuj Goel (Chief Development Officer) and Susheel Umesh (Chief Commercial Officer – Emerging Markets) as Senior Management Personnel.

Incentives and compliance: LTIP approval and trading window

To align employee incentives with long-term goals, the board approved the Biocon Unity Long Term Incentive Plan 2026, described as covering stock-based incentives and purchase plans for eligible employees across the company and its subsidiaries. The material also disclosed the trading-window closure period linked to results: the trading window for company securities was closed from April 1, 2026 to May 9, 2026, and set to reopen on May 10, 2026.

Background: earlier BBL acquisition milestones referenced

The compilation also referenced a major step completed earlier in the year. Biocon said it completed an acquisition of 33.38 crore BBL shares and allotted 17.13 crore Biocon equity shares on a preferential basis on January 5, 2026, following an extraordinary general meeting held on December 31, 2025. The transaction details cited included BBL shares acquired via share swap of 26.19 crore and for cash of 7.18 crore, totalling 33.38 crore. Cash consideration paid was stated as USD 200 million, with an issue price per Biocon share cited as ₹405.78 in that transaction context. Post-transaction ownership was described as moving from around ~77% to ~94% of BBL on a fully diluted basis.

Key facts at a glance

Market impact and why investors track these items

The dividend recommendation gives shareholders a clear corporate-action calendar around the record date and AGM vote, with payment planned by the end of August 2026 if approved. The BBL consolidation actions are material because they change how the biologics business sits within the listed structure, and the company explicitly linked the move to streamlined reporting and governance. For investors, the preferential issue and share-swap mechanics matter because they set the number of new shares to be issued, the disclosed issue price, and the timeline for approvals and closing. The auditor change and board refresh are also closely watched governance signals, particularly when a group is executing large subsidiary consolidation transactions. Finally, the FY26 financial disclosures provided include multiple revenue and profit figures across excerpts, which underscores the need to rely on the final audited statements and exchange filings for the definitive numbers.

Conclusion

Biocon’s May 7, 2026 board meeting combined FY26 audited results, a 10% final dividend recommendation, and a defined plan to complete the remaining BBL stake acquisition through a preferential share issuance and share swap. The next milestones disclosed are the record date on July 3, 2026, the AGM vote on August 6, 2026, and the stated integration target of June 30, 2026, subject to approvals.